Cell Source, Inc.
CLCS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,898 | $1,578 | $1,996 | $1,323 |
| G&A Expenses | $0 | $2,605 | $2,179 | $2,695 |
| SG&A Expenses | $1,950 | $2,605 | $2,179 | $2,695 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $142 | $0 | $1 |
| Operating Expenses | $3,849 | $4,325 | $4,175 | $4,019 |
| Operating Income | -$3,849 | -$4,325 | -$4,175 | -$4,019 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$923 | -$996 | -$992 | -$1,454 |
| Pre-Tax Income | -$4,771 | -$5,321 | -$5,168 | -$5,472 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,771 | -$5,321 | -$5,168 | -$5,472 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.17 | -0.18 | -0.19 |
| % Growth | 11.8% | 5.6% | 5.3% | – |
| EPS Diluted | -0.15 | -0.17 | -0.18 | -0.19 |
| Weighted Avg Shares Out | 41,871 | 37,786 | 34,836 | 28,116 |
| Weighted Avg Shares Out Dil | 41,871 | 37,786 | 34,836 | 33,117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $1,168 | $1,049 | $992 | $1,361 |
| Depreciation & Amortization | $0 | $53 | $4,175 | $4,019 |
| EBITDA | -$3,603 | -$4,220 | $0 | -$93 |
| % Margin | – | – | – | – |